Tricyclic Diterpenoids Selectively Suppress Androgen Receptor-Positive Prostate Cancer Cells

Androgen receptor (AR) is a viable therapeutic target for lethal castration-resistant prostate cancer (CRPC), because the continued progression of CRPC is mainly driven by the reactivation of AR transcriptional activity. The current FDA-approved AR antagonists binding to ligand binding domain (LBD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekhon, Inderpal, Chen, Guanglin, Piri, Keyara, Shinkawa, Seiji, Ashong, Dennis, Zhang, Qiang, Wang, Guangdi, Chen, Qiao-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300971/
https://www.ncbi.nlm.nih.gov/pubmed/37375297
http://dx.doi.org/10.3390/molecules28124743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300971/
https://www.ncbi.nlm.nih.gov/pubmed/37375297
http://dx.doi.org/10.3390/molecules28124743

Ejemplares similares